Avanir Pharmaceuticals Inc  

(Public, NASDAQ:AVNR)   Watch this stock  
Find more results for AVNR
5.21
-0.06 (-1.14%)
Real-time:   9:43AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.20 - 5.25
52 week 2.62 - 6.00
Open 5.23
Vol / Avg. 1,578.00/1.92M
Mkt cap 891.36M
P/E     -
Div/yield     -
EPS -0.47
Shares 171.09M
Beta 0.96
Inst. own 69%
Aug 5, 2014
Q3 2014 Avanir Pharmaceuticals Earnings Release - Tentative - 4:00PM EDT - Add to calendar
Jun 24, 2014
Avanir Pharmaceuticals at JMP Securities Healthcare Conference - Webcast
Jun 3, 2014
Avanir Pharmaceuticals at Jefferies Global Healthcare Conference - Webcast
May 13, 2014
Avanir Pharmaceuticals at Bank of America Merrill Lynch Health Care Conference - Webcast
May 8, 2014
Avanir Pharmaceuticals at Deutsche Bank Healthcare Conference - Webcast
May 6, 2014
Q2 2014 Avanir Pharmaceuticals Earnings Conference Call - Webcast
May 6, 2014
Q2 2014 Avanir Pharmaceuticals Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -47.05% -100.15%
Operating margin -43.70% -94.77%
EBITD margin - -93.68%
Return on average assets -70.20% -93.13%
Return on average equity -277.90% -272.93%
Employees 267 -
CDP Score - -

Address

Suite 200, 20 Enterprise
ALISO VIEJO, CA 92656
United States - Map
+1-949-3896700 (Phone)
+1-949-3896701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

Officers and directors

Craig A. Wheeler Independent Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Keith A. Katkin President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Christine G. Ocampo CPA Principal Financial Officer, Vice President - Finance
Age: 41
Bio & Compensation  - Reuters
Joao Siffert M.D. Senior Vice President - Research and Development, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Gregory J. Flesher Senior Vice President - Corporate Development, Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Rohan Palekar Senior Vice President, Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Mark H. N. Corrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Hans Edgar Bishop Independent Director
Age: 49
Bio & Compensation  - Reuters
David J. Mazzo Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Corinne H. Nevinny Independent Director
Age: 54
Bio & Compensation  - Reuters